<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03844646</url>
  </required_header>
  <id_info>
    <org_study_id>49402</org_study_id>
    <secondary_id>P30DK116074</secondary_id>
    <nct_id>NCT03844646</nct_id>
  </id_info>
  <brief_title>Continuous Glucose Monitoring to Aid Weight Loss in Prediabetes</brief_title>
  <official_title>Real-Time Continuous Glucose Monitoring to Aid Weight Loss in Prediabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine whether intermittent use of continuous&#xD;
      glucose monitor will facilitate weight loss in individuals who are overweight/obese with&#xD;
      prediabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Continuous glucose monitoring (CGM) has revolutionized the treatment of patients on intensive&#xD;
      insulin therapy and its utility can also be harnessed to help individuals with prediabetes&#xD;
      make healthful lifestyle changes. Successful weight loss requires adherence to lower&#xD;
      calories, regular exercise, and self-monitoring. This proposal will test the hypothesis that&#xD;
      intermittent CGM will facilitate all of these components for successful weight loss by&#xD;
      functioning as a continuous self-monitor and guiding healthful food choices and physical&#xD;
      activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    COVID-19&#xD;
  </why_stopped>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of weight lost (kg)</measure>
    <time_frame>Baseline to end of study (3 months)</time_frame>
    <description>Weight lost during the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in moderate physical activity</measure>
    <time_frame>Baseline to end of study (3 months)</time_frame>
    <description>Change in number of minutes of moderate physical activity (brisk walking)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Weight Loss</condition>
  <condition>PreDiabetes</condition>
  <arm_group>
    <arm_group_label>CGM plus dietitian</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermittent use of a continuous glucose monitor (CGM) plus dietitian support</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dietitian only</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dietitian support only</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CGM</intervention_name>
    <description>Intermittent use of a continuous glucose monitor (CGM)</description>
    <arm_group_label>CGM plus dietitian</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dietitian</intervention_name>
    <description>Monthly meetings with a dietitian</description>
    <arm_group_label>CGM plus dietitian</arm_group_label>
    <arm_group_label>Dietitian only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Overweight/obese (BMI 25-40 kg/m2)&#xD;
&#xD;
          -  Prediabetes (fasting glucose 100-125 mg/dL and/or HbA1c 5.7-6.4%)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  On glucose-lowering medications (e.g., metformin)&#xD;
&#xD;
          -  On weight-loss medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sun Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2019</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Sun H Kim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

